178 related articles for article (PubMed ID: 28621318)
1. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Alderdice M; Dunne PD; Cole AJ; O'Reilly PG; McArt DG; Bingham V; Fuchs MA; McQuaid S; Loughrey MB; Murray GI; Samuel LM; Lawler M; Wilson RH; Salto-Tellez M; Coyle VM
Mod Pathol; 2017 Sep; 30(9):1287-1298. PubMed ID: 28621318
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy.
Rogers AC; Gibbons D; Hanly AM; Hyland JM; O'Connell PR; Winter DC; Sheahan K
Mod Pathol; 2014 Jan; 27(1):156-62. PubMed ID: 23887296
[TBL] [Abstract][Full Text] [Related]
3. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
Jung JH; An HJ; Kim HJ; Lee J; Lee KM; Kim SH; Cho HM; Shim BY
Korean J Intern Med; 2016 Jan; 31(1):134-44. PubMed ID: 26767867
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
Park IJ; You YN; Agarwal A; Skibber JM; Rodriguez-Bigas MA; Eng C; Feig BW; Das P; Krishnan S; Crane CH; Hu CY; Chang GJ
J Clin Oncol; 2012 May; 30(15):1770-6. PubMed ID: 22493423
[TBL] [Abstract][Full Text] [Related]
7. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
[TBL] [Abstract][Full Text] [Related]
11. Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?
Choi JP; Kim SJ; Park IJ; Hong SM; Lee JL; Yoon YS; Kim CW; Lim SB; Lee JB; Yu CS; Kim JC
Oncotarget; 2017 Feb; 8(6):10375-10384. PubMed ID: 28060748
[TBL] [Abstract][Full Text] [Related]
12. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
13. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
14. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
15. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
17. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
Shinto E; Omata J; Sikina A; Sekizawa A; Kajiwara Y; Hayashi K; Hashiguchi Y; Hase K; Ueno H
BJS Open; 2020 Apr; 4(2):301-309. PubMed ID: 32026629
[TBL] [Abstract][Full Text] [Related]
18. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
